Cited 2 times in
A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.